Zivanovic A, Weng CF, , et al. - This study was intended to describe the outcomes of a prospective testing program established to evaluate the feasibility of circulating tumor DNA (ctDNA) analysis to guide clinical management of mBC patients. Researchers included 234 mBC patients (median age 54 years) between June 2015 and October 2018 at the Peter MacCallum Cancer Centre, Melbourne, Australia. Fifteen months (range 1–46) were the median follow-up. The prospective ctDNA testing was found to be a practical and beneficial procedure that can assist clinical trial enrolment and patient management in mBC.